IP Library Granted Patent US 7,335,355
Granted Patent B2
US 7,335,355 · App. 10/333,319 · Granted Feb 26, 2008

Antimicrobial agent

Assignee: Hansa Medical AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,335,355
App. No.
10/333,319
Granted
Feb 26, 2008
Kind
B2
Abstract

A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the test agent; (v) monitoring the survival of the bacterial culture thereby determining whether the test agent is capable of enhancing anti-microbial activity wherein a test agent capable of enhancing anti-microbial activity promotes killing of the bacterial culture. Agents identified by such a method are useful in the therapy of acute and chronic infections, particularly in the treatment of ulcers and in the promotion of wound healing.

Claims (7)

1. A method to identify an agent that inhibits the binding interaction between a glycosaminoglycan released by a bacterial extracellular proteinase and a cellular cationic anti-microbial peptide comprising the steps of: (i) providing a glycosaminoglycan released by a bacterial extracellular proteinase as a first component; (ii) providing a cellular cationic anti-microbial peptide as a second component; (iii) contacting the first and second components with a test agent wherein said first and second components would interact under the same conditions in the absence of said test agent, and (iv) monitoring any binding interaction between the first and second components thereby determining whether said test agent inhibits the binding interaction between the first and second components.

2. The method according to claim 1 , wherein the cationic anti-microbial peptide is a defensin.

3. The method according to claim 2 , wherein the defensin is an alpha-defensin.

4. The method according to claim 1 , wherein the cationic anti-microbial peptide is LL-37.

5. The method according to claim 1 , wherein the glycosaminoglycan has a high iduronate content.

6. The method according to claim 1 , wherein said glycosaminoglycan has a high degree of sulfation.

7. The method according to claim 1 , wherein said glycosaminoglycan is dermatan sulfate.

Assignments (2)
CHANGE OF NAME Recorded Feb 24, 2020
From: HANSA MEDICAL AB
To: HANSA BIOPHARMA AB
Reel/Frame 052002/0992 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2003
From: BJORCK, LARS; FRICK, INGA-MARIA; SCHMIDTCHEN, ARTUR
To: HANSA MEDICAL AB
Reel/Frame 014193/0093 →
Priority Claims (1)
EP 00306074 · Jul 17, 2000 · regional
Continuity (1)
Related Publication 20040028672A1 · Feb 12, 2004